NCT00871403View on ClinicalTrials.gov

Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Lung Cancer, Non-Small Cell
Interventions
DRUG

pazopanib and pemetrexed

oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m\^2 once every 3 weeks, then pazopanib 800 mg once daily

DRUG

pemetrexed and cisplatin

pemetrexed IV 500 mg/m\^2 and cisplatin IV 75 mg/m\^2 once every 3 weeks

Trial Locations (2)

2730

GSK Investigational Site, Herlev

SM2 5PT

GSK Investigational Site, Sutton

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY